The future is bright for prostate cancer research. It's glowing, in fact, thanks to new tools that combine the eye-catching ...

Lymphomas belong to the group of malignant diseases of the immune system and mainly affect the organs of the lymphatic system ...

A first-of-its-kind clinical trial will evaluate stem cell transplants with cells from deceased donors. (University of Utah ...

Rhenium-SCT is an epidermal radionuclide therapy that utilizes a radioisotope-based resin to treat shallow non-melanoma skin ...

Researchers at the Paul Scherrer Institute PSI have developed an AI that could open up a new, cost-effective approach to ...

First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research ...

In the largest clinical genomic profiling study of non-Hispanic Black men with metastatic prostate cancer to date, researchers from Moffitt Cancer Center, University of Pennsylvania, University of ...

This valuable study focuses on defining how the HSP70 chaperone system utilizes J-domain proteins to regulate the heat shock response-associated transcription factor HSF1. Using a combination of ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 trial.

Ireland’s SynOx Therapeutics has completed a second-round financing, raising $75 million, as it prepares to take its drug for tenosynovial giant cell tumour (TGCT) into phase 3 trials.

Like cancer, placental cells multiply rapidly, invade tissues, and evade destruction by the immune system, but maternal ...